INBX Stock — Inhibrx Biosciences Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential.

Source: 10-K FY2025 via SEC EDGAR

Share price

$84.52

Market cap

$1,243.9M

Cash

$133.3M

Enterprise value

$1,286.8M

Balance sheet

Cash	$133.3M
Debt	$176.3M
Net cash	-$42.9M
Enterprise value	$1,286.8M
Basic shares	14.7M shares
Fully diluted shares	19.3M shares
Fully diluted market cap	$1,631.2M
Cash per share	$9.07
Quarterly burn	$29.9M
Cash runway	4.5 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

14.7M

Pre-funded warrants

1.0M

Options

3.4M

RSUs

0.0M

Warrants

0.2M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

19.3M

Cap table as of 2026-06-30.

Price history

Loading INBX daily closes…

Loading price history…

Next catalyst

ozekibart (INBRX-109) · Apr 14, 2027 · guided in 5 mo

Recently reported

INBRX-106 Phase 2 Positive · 2026-09-08

INBRX-106 · head and neck squamous cell carcinoma (hnscc)

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDApr 14, 2027 in 5 mo	ozekibart (INBRX-109) BLA in conventional chondrosarcoma	Not disclosed	conventional chondrosarcoma	April 14, 2027 (PDUFA)
Jan 12 - Feb 23 in 27 mo	INBRX-109	Phase 1	Ewing Sarcoma; Colorectal Adenocarcinoma	—
Aug 12 - Sep 23 in 82 mo	INBRX-106 - Hexavalent OX40 agonist antibody	Phase 2	Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Ozekibart

Phase 3 · Active

Aliases INBRX-109

Target DR5

Indications

Conventional chondrosarcoma (Phase 3)
Colorectal cancer (Phase 1)
Ewing sarcoma (Phase 1)

Catalysts

— first quarter of 2027
— 2027

Status note Tetravalent DR5 agonist. Randomized chondrosarcoma trial completed (Oct 2025); FDA accepted BLA for filing in conventional chondrosarcoma (Jun 2026). Two new CRC Phase 1 cohorts initiated Q2 2026. FDA meeting planned Q4 2026 to discuss 1L registration path.

INBRX-106

Phase 2 · Active

Target OX40

Indications

Head and neck squamous cell carcinoma (Phase 2)
Non-small cell lung cancer (Phase 2)

Status note Hexavalent OX40 agonist. Randomized 1L Phase 2 portion of HexAgon study (with pembrolizumab) in PD-L1+ metastatic/unresectable recurrent HNSCC reported interim results May 2026; also being investigated in NSCLC.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	INBRX-106
Lead indication	Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead phase	Phase 3
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06295731	Phase 3	Active, not recruiting	Sponsor	INBX	—	Head and Neck Squamous Cell Carcinoma (HNSCC)	—
NCT04198766	Phase 2	Recruiting	Sponsor	INBX	MRK	Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer	—
NCT04950075	Phase 2	Active, not recruiting	Sponsor	INBX	—	Conventional Chondrosarcoma	—
NCT03715933	Phase 1	Recruiting	Sponsor	INBX	—	Ewing Sarcoma; Colorectal Adenocarcinoma	—
NCT06353997	Phase 2	Recruiting	Collaborator	Providence Health & Services	—	Triple Negative Breast Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Inhibrx Biosciences, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	1,297,763	-144,944	1.91%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

INBX — Inhibrx Biosciences Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

INBX — Inhibrx Biosciences Inc.